Investigating how DNMT3A mutations affect T-cell leukemia
JAK/STAT signaling in the pathogenesis of DNMT3A mutant T-ALL
This study is looking at how changes in a specific gene called DNMT3A affect T-cell acute lymphoblastic leukemia (T-ALL) and make it harder to treat, with the hope of finding new ways to help patients who have this type of leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10748361 on NIH RePORTER |
What this research studies
This research focuses on T-cell acute lymphoblastic leukemia (T-ALL), particularly how mutations in the DNMT3A gene contribute to the disease's progression and treatment resistance. By using genetic mouse models and analyzing human patient samples, the study aims to understand the role of JAK/STAT signaling pathways in making DNMT3A-mutant T-ALL cells more resistant to chemotherapy. The researchers are exploring how these mutations lead to increased sensitivity to certain cytokines, which may help identify new therapeutic strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with T-cell acute lymphoblastic leukemia, particularly those with DNMT3A mutations.
Not a fit: Patients without T-cell acute lymphoblastic leukemia or those with different genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with DNMT3A-mutant T-ALL, potentially enhancing their survival rates.
How similar studies have performed: Previous research has shown promising results in targeting JAK/STAT signaling in other cancers, suggesting potential for success in this area as well.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Challen, Grant Anthony — Washington University
- Study coordinator: Challen, Grant Anthony
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.